SavedAdd your journal

Journals / International Journal of Medical Biochemistry / 2020 / Cilt: 3 - Sayı: 3

Monocyte, neutrophil, eosinophil and lymphocyte volume levels in multiple myeloma patients

Esma MENEVSE
Abdullah SİVRİKAYA
Mehmet DAĞLI
Hamiyet KÖSE
Pages
166–170
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

And also, monocyte, lymphocyte and neutrophil volume levels are significant parameters that can be applied lower in cost.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Multiple myeloma (MM) is a malignant proliferation of monoclonal plasma cells in the blood that may also cause renal failure.
📊
Key Findings & Data:Seen from this aspect, it is indicated that inflammation is a significant component of the neoplastic process.
💡
Conclusion & Impact:And also, monocyte, lymphocyte and neutrophil volume levels are significant parameters that can be applied lower in cost.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: Multiple myeloma (MM) is a malignant proliferation of monoclonal plasma cells in the blood that may also cause renal failure. The most frequent complications of MM are painful pathological fractures, anemia, hyperkalemia, renal failure and recurrent bacterial infections. Seen from this aspect, it is indicated that inflammation is a significant component of the neoplastic process. Methods: The present study aims to evaluate the association of monocyte, neutrophil, eosinophil and leucocyte volume values in patients with MM as a retrospective study. Sixty patients with MM aged 64.5±11.2 and 107 healthy control aged 64.9±10.3 years who were admitted to the Polyclinic of Hematology in the Faculty of Medicine of the Selcuk University were included in this study. Results: The monocyte, lymphocytes, neutrophil volume levels were significantly higher in patients as 175.62±8.06; 95.05±6.08; 152.51±8.18, respectively, compared with the control group 170.41±8.15; 89.78±4.92; 148.19±8.04, respectively. The eosinophil volume levels were 157.5±22.4 in the patients group and 157±17.3 in the control group (p=0.953) The findings obtained in this study suggest that monocyte, lymphocytes, neutrophil volume values except eosinophil volume may be used a potentially prognostic biomarker in patients with Multiple myeloma. Conclusion: The present study aimed to evaluate a biomarker that is easily analyzed. This study suggests that monocyte, lymphocytes, neutrophil volume values except eosinophil volume may be used as a potentially prognostic biomarker in patients with Multiple myeloma. And also, monocyte, lymphocyte and neutrophil volume levels are significant parameters that can be applied lower in cost.

🔖

Cite This Article

MENEVSE, E., SİVRİKAYA, A., DAĞLI, M., KÖSE, H. (2020). Monocyte, neutrophil, eosinophil and lymphocyte volume levels in multiple myeloma patients. International Journal of Medical Biochemistry, Cilt: 3 - Sayı: 3, 166–170. https://ajindex.com/articles/207688

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351(18):1860–73
  2. Wu T, Zhou J, Wang C, Wang B, Zhang S, Bai H. Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report. Oncol Lett 2017;14(6):7318–22
  3. Freire-de-Lima L, Nardy AFFR, Ramos-Junior ES, Conde L, Santos Lemos J, da Fonseca LM, Lima JE, et al. Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response. Front Med (Lausanne) 2017;4:92
  4. Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, et al. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett 2016;371(1):117–24
  5. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010;116(18):3554–63
  6. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102(5):1115–23
  7. Liu, H, Xiong J, Zhang J, Zhang Y, Nie L, Wang Y, et al. Possible intrinsic association of anti-neutrophil cytoplasmic antibody-associated vasculitis coexisting with multiple myeloma. Oncol Lett 2016;12(3):2084–86
  8. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330(7):484–9
  9. Andersen MH. Anti-regulatory T cells. Semin Immunopathol 2017;39(3):317–26
  10. Ciocchini M, Arbelbide J, Musso CG. Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity. Int Urol Nephrol 2017;49(12):2171–5
  11. Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res 2017;5(1):3–8
  12. Wichert S, Pettersson Å, Hellmark T, Johansson Å, Hansson M. Bone marrow eosinophils in plasma cell disorders. Exp Hematol 2018;66:27–31.e5
  13. Moonim MT, Porwit A. Normal bone barrow histology. In: Porwit A, McCullough J, Erber WN, editors. Blood and Bone Marrow Pathology. 2nd ed. NY: Elsevier; 2011. p. 45–62
  14. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017;14(2):100–13
  15. Litma